Go Pro
NASDAQ:MDRX

Veradigm (MDRX) Stock Price, News & Analysis

Veradigm logo
$4.90 -0.10 (-2.00%)
As of 08/14/2026 03:14 PM Eastern

About Veradigm Stock (NASDAQ:MDRX)

Advanced

Key Stats

Today's Range
$4.55
$4.90
50-Day Range
$4.65
$5.18
52-Week Range
$3.00
$6.00
Volume
2,105 shs
Average Volume
129,230 shs
Market Capitalization
$599.27 million
P/E Ratio
23.25
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Veradigm, Inc. (NASDAQ: MDRX) is a healthcare technology company that provides a comprehensive suite of clinical, financial and analytical solutions to medical practices, health systems and life sciences organizations. The company’s offerings are designed to streamline electronic health record (EHR) workflows, optimize revenue cycle management and improve patient engagement through integrated software modules and cloud-based platforms.

Veradigm’s product portfolio includes EHR and practice management systems tailored to ambulatory and specialty care settings, as well as revenue cycle management services that encompass billing, coding and claims processing. The company also delivers data-driven analytics and real-world evidence solutions that enable healthcare providers and researchers to derive insights from large clinical data sets, inform population health strategies and support clinical trial recruitment.

Headquartered in Chicago, Illinois, Veradigm primarily serves the United States market, supporting thousands of physician practices and healthcare facilities across all 50 states. The company maintains partnerships with major health systems, specialty societies and pharmaceutical firms, extending its reach into areas such as telehealth integration, patient outreach and post-acute care coordination. Veradigm’s cloud infrastructure is designed to meet industry security standards and facilitate interoperability with third-party health information exchanges.

Veradigm traces its roots to the clinical and financial solutions division of Allscripts Healthcare Solutions, which was rebranded and spun off in 2022 to focus exclusively on data-centric healthcare services. Led by an executive team with deep expertise in health information technology, the company continues to invest in platform enhancements, machine learning capabilities and strategic alliances aimed at advancing digital health initiatives and improving care delivery outcomes.

AI Generated. May Contain Errors.

Receive MDRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDRX Stock News Headlines

Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Veradigm Files 2023 and 2024 Form 10-K
See More Headlines

MDRX Stock Analysis - Frequently Asked Questions

Veradigm's stock was trading at $4.60 at the start of the year. Since then, MDRX shares have increased by 6.5% and is now trading at $4.90.

Veradigm Inc. (NASDAQ:MDRX) announced its quarterly earnings data on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.09. Veradigm's revenue was down 8.2% on a year-over-year basis.

Veradigm subsidiaries include ZappRx, HealthGrid, and Practice Fusion.

Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Veradigm investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/04/2021
Today
8/14/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Technology
Sub-Industry
Healthcare Technology
Current Symbol
NASDAQ:MDRX
CIK
1124804
Employees
8,000
Year Founded
1986

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
23.25
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.53 billion
Price / Sales
0.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
122,300,000
Free Float
105,175,000
Market Cap
$599.27 million
Optionable
No Data
Beta
0.54

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:MDRX) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners